Plenty, says Anthony Segreti, PhD ’77 (BIOS), a card-carrying member of the Society for American Baseball Research, the organization that has developed sabermetrics, the empirical analysis of baseball statistics. (Think about the 2011 Brad Pitt film, Moneyball, depicting a general manager who built a stellar team of undervalued players using sabermetrics.)
Baseball and pharma have some things in common, said Segreti. “Baseball teams draft and sign a lot of players to contracts and, of that number, only a few are going to make it to the major leagues. In the pharmaceutical industry, there are a lot of contenders but not a lot make it to the approval stage.
“You can have a lot of notoriety and expectations, but what really matters is how you perform on the field – or in the clinical trials. Everything is based on evidence, just like everything is based on how a player is able to succeed on the field.” And as in baseball, you can’t always win, he said. That’s part of the game.
Segreti joined the pharmaceutical industry in 1979 at Burroughs Wellcome Co., and remained there through mergers with Glaxo and SmithKline, until leaving in 2006 to work at two contract research organizations for a few years. He then joined biotechnology firm Targacept and remained there until his 2014 retirement.
To use another baseball analogy, Segreti made it to the show. At the Department of Biostatistics graduation ceremony on May 12, he shared stories of some big wins.
Those include being in the lineup in the development of some highly successful drugs, including Acyclovir, an antiviral drug that started a new era in herpes treatment; Zidovudine, for HIV treatment; and epoprostenol sodium, a game-changer for pulmonary arterial hypertension. “Drug development is a team sport,” he noted.
And that’s where his training on the MCV Campus especially came into play.
“I always felt that VCU was a real springboard to my career. There’s a wonderful opportunity for graduate students to interact with researchers and solve real world problems and learn a lot of the activities you don’t learn in a textbook. You learn to be an effective consultant, researcher and how to get along with those who don’t see the world the way that you do.”
Because recruiting new talent to the field is important, he remains active in the Biopharmaceutical Applied Statistics Symposium (BASS), a forum where researchers and scholars in academia, government agencies and industries to share knowledge and ideas. He’s chairing this year’s meeting and working to support the next generation of biostatisticians who attend.
In addition to sharing his time and expertise with the Biostatistics Department and its students, Segreti and his wife, Wendy, have made several generous donations to the university. “There’s nothing I’d rather spend money on – outside my family – than giving something back to the university that really helped my career.”
He fondly recalls his years on the MCV Campus and how the biostatistics graduate students would exercise together during lunch. For two years in a row they won the intramural basketball championship of their league. “The joke was that nobody under 6 feet would get a scholarship,” he said.
Like many players, Segreti eventually worked as a manager, leading between 15 and 40 statisticians. Those professionals, he said, tend to like to work independently, so he knew he needed a special strategy.
Naturally, he looked to sports for a management philosophy, taking a cue from a famed baseball manager. “Tommy Lasorda said, ‘Managing is like holding a dove in your hand. Squeeze too hard and you kill it; not hard enough and it flies away.’”
By Lisa Crutchfield